Macquarie Group’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-942
| Closed | -$28.9K | – | 2122 |
|
|
2022
Q2 | $25K | Hold |
942
| – | – | ﹤0.01% | 2239 |
|
|
2022
Q1 | $32 | Hold |
942
| – | – | ﹤0.01% | 2277 |
|
|
2021
Q4 | $36K | Hold |
942
| – | – | ﹤0.01% | 2257 |
|
|
2021
Q3 | $51K | Buy |
+942
| New | +$44.2K | ﹤0.01% | 2229 |
|
|
2021
Q1 | – | Sell |
-4,874
| Closed | -$85K | – | 2466 |
|
|
2020
Q4 | $85K | Buy |
+4,874
| New | +$87.7K | ﹤0.01% | 1906 |
|
|
2019
Q1 | – | Sell |
-3,467
| Closed | -$10K | – | 1704 |
|
|
2018
Q4 | $10K | Hold |
3,467
| – | – | ﹤0.01% | 1923 |
|
|
2018
Q3 | $23K | Buy |
3,467
+1,060
| +44% | +$7.42K | ﹤0.01% | 1875 |
|
|
2018
Q2 | $18K | Buy |
+2,407
| New | +$32.2K | ﹤0.01% | 2071 |
|
|
2018
Q1 | – | Sell |
-193
| Closed | -$8K | – | 2197 |
|
|
2017
Q4 | $8K | Buy |
+193
| New | +$8.27K | ﹤0.01% | 2302 |
|
|
2016
Q1 | – | Sell |
-8,048
| Closed | -$1.89M | – | 1536 |
|
|
2015
Q4 | $1.89M | Buy |
8,048
+2,446
| +44% | +$533K | ﹤0.01% | 948 |
|
|
2015
Q3 | $886K | Buy |
5,602
+1,889
| +51% | +$535K | ﹤0.01% | 1153 |
|
|
2015
Q2 | $1.41M | Buy |
3,713
+733
| +25% | +$291K | ﹤0.01% | 1110 |
|
|
2015
Q1 | $1.25M | Sell |
2,980
-600
| -17% | -$215K | ﹤0.01% | 1105 |
|
|
2014
Q4 | $980K | Hold |
3,580
| – | – | ﹤0.01% | 1169 |
|
|
2014
Q3 | $696K | Hold |
3,580
| – | – | ﹤0.01% | 1213 |
|
|
2014
Q2 | $876K | Buy |
3,580
+1,667
| +87% | +$376K | ﹤0.01% | 1218 |
|
|
2014
Q1 | $507K | Buy |
1,913
+800
| +72% | +$306K | ﹤0.01% | 1280 |
|
|
2013
Q4 | $404K | Buy |
+1,113
| New | +$429K | ﹤0.01% | 1295 |
|
Other funds holding CLDX
RI
RCM
RG
BG
EAM